Adam Nitido

Research

Postdoctoral Fellow, Balazs Lab

The role of mutational bias in HIV-1 evolution

In the lab of Alejandro B. Balazs, I developed ERR-Seq, an assay of mutation rate and spectrum after a single round of replication that counts mutations before selection can remove them, so it measures what the virus makes independent of fitness cost.

From that dataset we built an HIV-1 Mutation Rate Atlas, which estimates the rate of every single-nucleotide change across the genome and the resulting mutability of each amino acid change. Mutation is highly uneven, and that bias predicts which drug resistance mutations emerge in people living with HIV-1, even when controlling for fitness cost.

This work is described in HIV-1 Mutational Bias Shapes the Supply of Drug Resistance Mutations, with Nartşav Ömür and Alejandro B. Balazs. It is not yet published.

HIV-1 escape dynamics from broadly neutralizing antibodies

With Nicolás M. S. Gálvez, I am co-first author of a 2026 Immunity paper on why some broadly neutralizing antibodies suppress HIV in vivo while others fail, even when they appear equally potent in vitro. Potency and breadth alone do not explain the therapeutic outcome. It tracks the evolutionary escape barrier facing the virus.

Using AAV-delivered antibodies in humanized mice, we found that escape paths are highly conserved for each antibody. We projected those mutations onto fitness landscapes, balancing the benefit of resistance against the cost to replication. The resulting escapability maps explain the treatment outcomes.

When we increased the fitness cost of escape, partial suppression became durable control. These therapies should be designed for breadth and potency, and also to raise the evolutionary cost of resistance.

Development of haplotype-based HIV-1 sequencing methods

I am developing high-throughput haplotype-based sequencing methods for HIV-1.